ADAR1 Capital Management »

Denali Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Denali Therapeutics (DNLI) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Denali Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Denali Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Denali Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $41k 2.0k 20.52

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Denali Therapeutics

BlackRock
Baillie Gifford & Co
BlackRock
Vanguard Group
Capital Research Global Investors
Crestline Management
State Street Corporation
Baker Bros. Advisors
Geode Capital Management
T. Rowe Price Associates
Alliancebernstein
Marshall Wace
Dimensional Fund Advisors
Bank of New York Mellon
Principal Financial Group

View all funds holding Denali Therapeutics